🇺🇸 FDA
Pipeline program

DS-3939a

DS3939-077

Phase 2 small_molecule active

Quick answer

DS-3939a for Metastatic Solid Tumor, Advanced Solid Tumor is a Phase 2 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Daiichi Sankyo Europe GmbH
Indication
Metastatic Solid Tumor, Advanced Solid Tumor
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials